Amid a projected uptick in the prevalence of chronic diseases for an increasingly aging population, it’s more imperative than ever for patients to have access to the therapies they need to treat their health conditions. To improve patient access, stakeholders across the industry have turned to real-world data (RWD) to uncover critical insights into the patient journey—from social determinants of health to diagnoses, treatment, and outcomes.
With the Center for Drug Evaluation and Research approving nearly 43 novel drugs per year, pharmaceutical (pharma) companies are recognizing the value of claims, lab, and electronic health record (EHR) data to paint a holistic picture of the market environment before launching a new drug. RWD-generated insights help manufacturers identify areas of need, understand access barriers and the full patient journey, and plan a successful drug launch.
By augmenting traditional market access data with RWD from claims, labs, and the EHR, pharma manufacturers will be better equipped to launch novel therapies, overcome patient access barriers, and improve outcomes for patients in need.
For more on how claims, lab and EHR data are crucial for drug launches, read the full article on Pharmacy Times.
